Bioengineered H-Ferritin Nanocages for Quantitative Imaging of Vulnerable Plaques in Atherosclerosis

Minmin Liang,†# Hui Tan,‡,# Jun Zhou,† Tao Wang,§ Demin Duan,† Kelong Fan,† Jiuyang He,† Dengfeng Cheng,*‡ Hongcheng Shi,*‡ Hak Soo Choi,*∥ and Xiyun Yan*†

†Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
‡Department of Nuclear Medicine, Zhongshan Hospital, Fudan University/Shanghai Institute of Medical Imaging, Shanghai 200032, China
§Peking University Third Hospital, Beijing 100191, China
∥Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States

Supporting Information

ABSTRACT: Inflammation and calcification concomitantly drive atherosclerotic plaque progression and rupture and are the compelling targets for identifying plaque vulnerability. However, current imaging modalities for vulnerable atherosclerotic plaques are often limited by inadequate specificity and sensitivity. Here, we show that natural H-ferritin nanocages radiolabeled with technetium-99m (99mTc-HFn) can identify and accurately localize macrophage-rich, atherosclerotic plaques in living mice using combined SPECT and CT. Focal 99mTc-HFn uptake was observed in the atherosclerotic plaques with multiple high-risk features of macrophage infiltration, active calcification, positive remodeling, and necrosis on histology and in early active ongoing lesions with intense macrophage infiltration. The uptake of 99mTc-HFn in plaques enabled quantitative measuring of the dynamic changes of inflammation during plaque progression and anti-inflammation treatment. This strategy lays the foundation of using bioengineered endogenous human ferritin nanocages for the identification of vulnerable and early active plaques as well as potential assessment of anti-inflammation therapy.

KEYWORDS: atherosclerosis, vulnerable plaque, H-ferritin, SPECT imaging, PET imaging

Atherosclerotic plaque rupture results in thrombus formation and vessel occlusion and is the leading cause of death worldwide. Many infarcts originate from nonobstructive vulnerable plaque that cannot be identified by conventional diagnostic modalities, such as stress testing or aortic angiography, making it difficult to predict such vascular events. Since the major determinants for acute clinical events are found to be the biological compositions of atherosclerotic plaques rather than the degree of stenosis, the primitive approach in identifying such active biological compositions associated with high-risk plaques is the use of modern molecular imaging techniques in conjunction with targeted imaging agents. Of these high-risk plaque compositions, inflammation and calcification concomitantly drive atherosclerotic plaque progression and rupture and are compelling targets for identifying plaque vulnerability. To date, molecular imaging of vascular inflammation with 18F-fluorodeoxyglucose (18F-FDG) and calcification activity with 18F-sodium fluoride (18F-NaF) has been widely investigated for identifying vulnerable plaque. Particularly, 18F-FDG is also currently proposed as the noninvasive gold standard for atherosclerotic plaque vulnerability identification through detecting vascular inflammation and macrophage burden. However, its clinical impact has been minimal because the high myocardial metabolic uptake of 18F-FDG renders the interpretation of the signal as originating from coronary plaques. In addition, the limited spatial resolution of PET (~2 mm) and the small size of vascular plaques consequently require a high degree of focal 18F-FDG accumulation. This is a...
Representative ex vivo prepared by the radiolabeling of HFn with 99mTc using FDG and the promising calcification activity imaging agent 18F-NaF. Potential more specific radiotracers for inflammation and better-suited for vascular lesions imaging are highly sought after for atherosclerosis characterization.

Ferritin is a self-assembled spherical iron storage protein nanocage composed of 24 subunits of two types: heavy-chain ferritin (HFn) and light-chain ferritin (LFn). Increased levels of HFn proteins have been found to accumulate in the macrophages infiltrated into human atherosclerotic plaques. Natural HFn may therefore reflect atherosclerotic progression via reporting macrophage accumulation within plaques. McConnel and colleagues examined the feasibility of using human ferritins for imaging vascular macrophages after conjugating with fluorophores or encapsulated magnetite nanoparticles. We recently reported that human HFn specifically binds to tumor cells via transferrin receptor 1 (TfR1), which is highly expressed in the infiltrated macrophages within atherosclerotic plaques and significantly associated with the increasing risk of plaque rupture. We therefore investigated the use of bioengineered human HFn radiolabeled with 99mTc (99mTc-HFn) to identify vulnerable atherosclerotic plaques in vivo and validated its specific activity by comparison with the current noninvasive gold standard 18F-FDG and the promising calcification activity imaging agent 18F-NaF.

RESULTS

**99mTc-HFn Images Vulnerable Atherosclerotic Plaques in Vivo.** Bioengineered human HFn nanocages were prepared as described previously. 99mTc-HFn was prepared by the radiolabeling of HFn with 99mTc using N-hydroxysuccinimide ester MAG3 as an intermediate chelator (Supplementary Figure S1a), the radiochemical purity of which was confirmed by thin-layer chromatography (>98%; Supplementary Figure S1b). After purification, the prepared 99mTc-HFn nanocages were characterized by cryo-electron microscopy (cryo-EM) and dynamic light scattering (DLS). 99mTc-HFn shows a well-defined morphology and is monodisperse with an outer hydrodynamic diameter of ∼16 nm (Supplementary Figure S1c). The labeling stability of 99mTc-HFn was measured by monitoring 99mTc release over the course of incubation in fetal bovine serum at 37 °C. A radiochemical purity of >80% was detected after 12 h of serum incubation (Supplementary Figure S2), suggesting that 99mTc-HFn is stable enough during systemic circulation that it allows sufficient time for specific target uptake.

We evaluated the feasibility of atherosclerotic imaging with 99mTc-HFn in apolipoprotein E-deficient mice (Apoe−/−) fed with a high-fat diet for 12, 20, or 33 wk, respectively, to develop varying degrees of atherosclerotic plaque buildup. Wild-type C57 mice were used as disease controls. The progressive development of atherosclerotic plaques in Apoe−/− mice was confirmed by Oil Red O staining of the aortas excised from Apoe−/− mice (Supplementary Figure S3).

We performed single-photon emission computed tomography/computed tomography (SPECT-CT) imaging 2 h postintravenous administration of 99mTc-HFn in atherosclerotic and control mice. As shown in Figure 1a, intense focal radiotracer uptake was observed in the aortas of atherosclerotic mice, whereas only scant uptake in the control mice was observed. As the atherosclerosis progressed, the radiotracer uptake in the aortas of atherosclerotic mice increased constantly from 0.597 ± 0.262%ID/mL at 12 wk to 1.659 ± 0.526%ID/mL at 20 wk and 2.767 ± 0.379%ID/mL at 33 wk, strongly correlated with the corresponding plaque areas quantified by aortic Oil-Red O staining (r² = 0.87, ***P = 0.001) (Figure 1b). This result demonstrates the feasibility of imaging atherosclerotic plaques with 99mTc-HFn.

![Figure 1](Image 102x533 to 522x749)
After in vivo imaging, the mice were sacrificed, and ex vivo planar imaging of the excised aortas was performed through gamma imaging. As shown in Figure 1c, intense radioactivity uptake (yellow-red) was localized to the sites of atherosclerotic plaques (Oil Red O staining-positive areas) in all Apoe−/− mice. No atherosclerotic plaques or specific radioactivity accumulation was present in aortas of control mice.

After ex vivo imaging, we characterized the 99mTc-HFn-positive region using histology. As shown in Supplementary Figure S4, focal 99mTc-HFn uptake occurred at the plaque region, showing histological evidence of intense macrophage infiltration (Mac-3 staining), active calcification (von Kossa staining), positive remodeling, thin fibrous cap (≤65 μm), and large necrotic cores (H&E staining) in morphology, indicating...
the formation of high-risk atherosclerotic plaques. These results show that $^{99m}$Tc-HFn images vulnerable plaques.

We then demonstrated that $^{99m}$Tc-HFn accumulated into atherosclerotic plaques via specific binding to plaque-infiltrated macrophages. As shown in Figure 2, histology of the $^{99m}$Tc-HFn-positive plaque region from the excised aorta showed intense macrophage infiltration (Mac-3 staining) and a strong correlation between $^{99m}$Tc-HFn uptake and the extent of macrophage infiltration within plaques ($***$ $P < 0.001$, $r^2 = 0.83$; Figure 2a). Immunofluorescent staining of the $^{99m}$Tc-HFn-positive plaque region demonstrated colocalization of HFn staining with macrophages (Mac-3 staining; Figure 2b), indicating that HFn specifically binds to macrophages within plaques. We further isolated the plaque-infiltrated CD11b+F4/80$^+$ macrophage cells and characterized their binding specificity with HFn (Figure 2c). The binding of HFn to plaque macrophages was saturable and could be inhibited by adding an excess of unlabeled HFn (Figure 2d, left), confirming the binding specificity of HFn to plaque macrophages. The saturation binding curve and Scatchard analysis demonstrate that the $K_d$ value for HFn is 54.2 nM and the total binding capacity $B_{max}$ is $34.6 \times 10^{-10}$ mol/cell (Figure 2d, right), indicating a high binding affinity and capacity of HFn for plaque-infiltrated macrophages. This is highly valuable because macrophage-rich inflammation is an obligatory component of active plaques and is particularly intense in the high-risk plaque.28-30

To further confirm the binding specificity of the $^{99m}$Tc-HFn to macrophages in vivo, we injected fluorescein isothiocyanate (FITC)-labeled HFn (FITC-HFn) intravenously into ApoE$^{-/-}$ mice and characterized the plaque region from the excised aorta using fluorescent histology. As shown in Supplementary Figure S5, FITC-HFn signals (green) were colocalized to the Mac-3-positive macrophages (red, anti-Mac-3 staining) within plaques. This result further confirms that HFn nanocages accumulate in atherosclerotic plaques via specific binding to plaque-infiltrated macrophages.

Pharmacokinetics and biodistribution studies revealed a rapid blood clearance half-life ($t_{1/2}$) of 2.32 min (Supplementary Figure S6) as well as high aorta-to-background ratios against vertebrae, heart, and muscle of 7.22, 3.54 and 9.75, respectively, at the imaging time point (Supplementary Table S1). This result proves that a clear vessel wall imaging can be obtained using $^{99m}$Tc-HFn because of the low background uptake around the whole aorta from the aortic arch to the thoracic aorta and abdominal aorta.

Comparison of $^{99m}$Tc-HFn and $^{18}$F-FDG Imaging. $^{18}$F-FDG PET has been used generally for noninvasive imaging of vascular inflammation. We next compared the in vivo performance of $^{99m}$Tc-HFn with $^{18}$F-FDG. We injected $^{18}$F-FDG tracer intravenously into ApoE$^{-/-}$ mice ($n = 8$) and wild-type C57 mice ($n = 5$) and obtained PET images at 2 h postinjection (Supplementary Figure S7). $^{18}$F-FDG accumulated in the organs with high metabolism or excretion, including the heart, brown adipose tissue, bladder, vertebrae, etc. In particular, $^{18}$F-FDG uptake in the target adjacent vertebrae and myocardium was higher than the signals originated from aortic plaques in ApoE$^{-/-}$ mice, which makes the plaque uptake barely distinguishable from background signal. In contrast, intense focal $^{99m}$Tc-HFn uptake was present at the site of aortic plaque with a clear neighboring background that demonstrates a discernible and quantifiable plaque uptake (Supplementary Figure S7a), as further confirmed by the biodistribution data (Supplementary Table S1). There is no quantitative analysis present for $^{18}$F-FDG images because no discernible plaque uptake was observed in murine aorta (Supplementary Figure S7b), even from 16 consecutive tomographic images covering the entire murine aorta (Supplemental Figure 7c). Although $^{18}$F-FDG imaging was hampered by the problem of high background signals, it remains an important measure of general vascular inflammation in the aorta and carotid arteries, providing complementary and distinct metabolic information to that of $^{99m}$Tc-HFn uptake.

Figure 3. Inflammatory infiltration and calcification activity within progressive plaques. Representative serial sections of each group were detected by anti-Mac-3 antibody for macrophages and von Kossa staining for active calcifications. Early plaques (12 wk plaques) show no evidence of active calcification while yielding marked macrophage staining. Prominent calcification and macrophage infiltration are present in advanced plaques (20 and 33 wk plaques). Arrows in the right panel indicate calcific deposits (right panel).
**Combining of $^{99m}$Tc-HFn and $^{18}$F-NaF Imaging.** Active calcification is another major characteristic of vulnerable atherosclerotic plaques, which is strongly associated with vascular inflammation, and they both largely drive atherosclerotic plaque progression and rupture. A comprehensive understanding and characterization of inflammatory infiltration and active calcification of atherosclerotic plaques offer complementary information for identifying plaque vulnerability. Many studies have recently shown the feasibility of $^{18}$F-NaF to detect active calcification. We therefore investigated whether $^{99m}$Tc-HFn could be combined with $^{18}$F-NaF to monitor inflammatory infiltration together with active calcification during the progression of atherosclerosis. We imaged plaque calcification activity in the aortas excised from atherosclerotic and control mice 2 h postintravenous administration of $^{18}$F-NaF. As shown in Supplementary Figure S8, no significant $^{18}$F-NaF uptake was detected in whole aortas from atherosclerotic mice at 12 wk after initiation of the atherogenic diet along with high $^{99m}$Tc-HFn uptake. This demonstrates that inflammatory infiltration within plaques occurred earlier than calcification, indicating that $^{99m}$Tc-HFn is a better targeted radiotracer than $^{18}$F-NaF for identifying early active atherosclerosis. In later stages of the disease, both intense $^{99m}$Tc-HFn and $^{18}$F-NaF activities were observed at the sites of atherosclerotic lesions (Figure 1c, Supplementary Figure S8a), indicating both severe inflammatory infiltration and calcification deposition occurred within the plaques. $^{99m}$Tc-HFn is therefore more favorable for monitoring the initiation of active ongoing plaques than $^{18}$F-NaF, and the combined $^{99m}$Tc-HFn and $^{18}$F-NaF can monitor the inflammatory infiltration together with active calcification in latter stages of the disease.

In the following histological validation, we further identified no active calcification by von Kossa staining at the 12 wk time point section, while exhibiting obvious macrophage staining in the corresponding serial sections (Figure 3, top). With disease progression and severity, advanced plaques at 20 and 33 wk represent both prominent calcification activity and increased macrophage burden (Figure 3, middle and bottom). Therefore, $^{99m}$Tc-HFn and $^{18}$F-NaF can complement each other for atherosclerosis characterization by imaging plaque inflammation and active calcification, respectively, throughout the whole progression of atherosclerosis.

**Monitoring of Anti-inflammatory Treatment with $^{99m}$Tc-HFn in Atherosclerosis.** In current clinical settings, patients with plaques are usually treated with statin anti-inflammatory therapy for prevention and treatment of coronary and carotid artery diseases. Therefore, quantitative monitoring of the anti-inflammatory treatment by using noninvasive imaging helps guide the current treatment strategies and assist in the development of novel treatment drugs.

We assessed the statin therapeutic effects on early and advanced stage atherosclerosis (9 and 21 wk after an atherogenic diet) in Apoe$^{−/−}$ mice by subjecting each of them to a 12 wk treatment (Figure 4a). $^{99m}$Tc-HFn uptake was used to monitor the dynamic changes of inflammation in atherosclerotic plaques during plaque progression and anti-inflammatory treatment. Early stage treatment significantly
prevented the progression of atherosclerosis as compared with the control group without statin treatment, while less significant effects were observed in the advanced-stage treatment group (Figure 4b,c). Histology identified that the macrophage burden and calcification activity were also prevented more effectively by statin therapy in early atherosclerosis than advanced stage treatment (Figure 4d). Thus, early initiation of statin treatment is crucial to plaque formation prevention, since inflammation occurs in early stages of atherosclerosis. Furthermore, this indicates that 99mTc-HFn uptake can provide a useful approach to assess antithrombolytic therapy.

DISCUSSION

Natural human ferritin and its binding receptor, TfR1, are known to accumulate greatly in the infiltrated macrophages within atherosclerotic plaques and are significantly associated with increased risk of plaque rupture.22 We identified that the bioengineered H-ferritin bound to the plaque-infiltrated macrophages with high specific binding affinity (Kd = 54.2 nM) and capacity (Bmax = 34.6 × 10^-19 mol/cell). By utilizing the intrinsic macrophage-binding property, we demonstrated that 99mTc-HFn can identify vulnerable plaques and early active ongoing plaques in living mice via combined SPECT and CT. Intensive focal 99mTc-HFn uptake was observed in the atherosclerotic plaques, which is associated with high-risk histological features of active calcification, macrophage infiltration, positive remodeling, and necrosis; these observations were made in the early active plaques with prominent macrophage infiltration as well. Furthermore, the dynamic changes of inflammation in plaques during anti-inflammation treatment was quantitatively monitored by 99mTc-HFn uptake. 99mTc-HFn therefore holds a major promise for identifying high-risk atheroma and potentially assessing anti-atherosclerotic therapy.

99mTc-HFn SPECT represents an advance for prevention and treatment of atherosclerosis and may have a medical impact for the following reasons: (1) Identification of vulnerable plaques: The current diagnostic strategies still cannot identify high-risk vulnerable plaques before they rupture and subsequent clinical symptoms appear. Therefore, patients get treatment after atherosclerotic plaque rupture initiates myocardial and cerebral infarctions, which remains the leading cause of death worldwide. 99mTc-HFn can identify and accurately localize vulnerable atherosclerotic plaques in living mice by specifically binding to plaque-infiltrated macrophages, which thus represents a potential clinical advance for prevention and treatment of coronary and carotid artery diseases. (2) Evaluation of statin prescribing: In current clinical therapy, and thus has a potential medical impact on the treatment of atherosclerosis.

Although there are several types of nanomaterials, such as iron oxide and gold NPs coated with dextran or high-density lipoprotein, that have been reported for imaging macrophages in atherosclerosis, the bioengineered HFn nanocages described herein present the following points of advantages over existing nanoprobes: (1) Specificity: Most macrophage-specific NPs rely on their natural endocytoses, which are predominantly internalized by circulating monocytes and tissue macrophages in lymph nodes, liver, spleen, and bone marrow.44 On the other hand, HFn nanocages bind to plaques through TR1-mediated specific targeting, showing clear vessel wall imaging with little background uptake including the target adjacent bone marrow (Figure 1a and Table S1). (2) Biodegradability: Most macrophage-specific NPs are relatively large, 10–300 nm in diameter, and typically nonbiodegradable.35,36 Therefore, these NPs accumulate nonspecifically in the reticuloendothelial system, including the spleen and liver, and are potentially toxic to the immune system. HFn nanocages exist naturally in humans and are composed of nontoxic globular proteins (8–12 nm); therefore, they would not activate inflammatory or immunological responses.25–27 (3) Simplicity: HFn nanocages are produced from Escherichia coli at a high yield (>100 mg/L from the bacterial lysate) and can be used for further modification with radiolabeling or fluorescence labeling.

CONCLUSIONS

There is an unmet clinical need to develop radiotracers that can identify vulnerable and early active atherosclerotic plaques to prevent and treat myocardial infarction and ischemic stroke. In this study, we demonstrated the specific uptake of iron-storage nanocage HFn to the infiltrated macrophages within the high-risk plaques as well as in early active ongoing atherosclerotic plaques. The high target specificity, low myocardial and background activities, and high sensitivity for vulnerable and early active plaques give advantages to 99mTc-HFn over the use of 18F-FDG for atherosclerosis imaging. The ability to monitor plaque progression and treat it with anti-inflammatory interventions supports the vascular 99mTc-HFn uptake as a potential noninvasive imaging radiotracer to identify high-risk atheroma and potentially assess anti-atherosclerotic therapy.

MATERIALS AND METHODS

Preparation and Characterization of 99mTc-HFn. Human HFn was produced in E. coli and purified as previously described.25,26 N-Hydroxysuccinimidy1 S-acetylmercaptoacetyltrimethylamine (NHS-MAG) was synthesized in-house and conjugated to HFn via the derivatized amine as previously described.37 MAG-conjugated HFn (MAG-HFn) was radiolabeled with 99mTc-pertechnetate (99mTcO4−) (Shanghai GMS Pharmaceutical Co., Ltd.) by the following procedure. Briefly, a solution of 100 μg of MAG-HFn conjugates in 45 μL of ammonium acetate (0.25 M) was added to 15 μL of trituration buffer with 37 MBq of 99mTcO4−. After vortexing, 4 μL of freshly prepared 1 mg/mL SnCl2.2H2O solution was added. The mixture was incubated for 1 h at room temperature under vortexing. The final radiochemical yield of 99mTc-HFn was >98%. The labeling yield and radiochemical purity of the products were measured by instant thin-layer chromatography (ITLC) on a radio thin-layer scanner (Bioscan).

Animals. We used atherosclerotic apolipoprotein E knockout (ApoE−/−) mice (C57BL/6) background (ApoE−/−) mice (C57BL/6) background) for plaque imaging and therapeutic studies. Mice were fed with an atherogenic diet (containing 21% fat and 0.15% cholesterol by weight) starting at 9 wk of age. After consuming the atherogenic diet for 12, 20, or 33 wk, mice were used for imaging experiments. Therapeutic groups were given 12 wk of atorvastatin therapy with 10 mg/kg/d at 9 or 21 wk after beginning the atherogenic diet. Age-matched wild-type C57BL/
6j mice on normal chow were used as disease controls. All animals were fasted overnight before use for imaging experiments. Protocols were performed with the approval of the Ethical Committee of Zhongshan Hospital, Fudan University.

**99mTc-HFn SPECT-CT Imaging.** Atherosclerotic and control mice were intravenously administered 99mTc-HFn with a dose of 500 μCi (99mTc) and 100 μg (HFn) per mouse in 100 μL of saline. Two hours after injection, anesthetized mice were imaged on a small-animal nano-SPECT/CT system (Bioscan). SPECT and CT acquisitions were reconstructed, fused, and quantified using dedicated software, InVivoScope (version 1.43, Bioscan). Spatial resolution was 1 mm/ pixel for SPECT imaging. Regions of interest (ROIs) were manually drawn in the aorta where obvious radioactivity was present. SPECT scale was normalized to %ID/mL to allow direct visual comparison between animals. The high background uptake of liver and bladder were automatically removed from the images by the postprocessing software (InVivoScope; Invicro, Boston, MA, USA).

After in vivo imaging, the mice were sacrificed and aortas were immediately excised for ex vivo planar imaging using a gamma camera (Dilon 6800, Dilon Technologies) with the following parameters: collimator, low-energy general-purpose; peak energy, 140 keV; window width, ±10%; matrix, 80 × 80; resolution, 0.32 mm/pixel. The collection time was 30 min with total counts of 80 000–100 000.

**18F-FDG and 18F-NaF PET Imaging.** Atherosclerotic and control mice were intravenously injected with 200 μCi of [18F-FDG] or [18F-NaF] per mouse in 100 μL of saline. Mice were anesthetized with 2% isoflurane inhalation 2 h postinjection and imaged on a Nano PET scanner (Shandong Madic Technology, China). Depending on the count rate, PET images were acquired for 20 min and then reconstructed using a two-dimensional ordered-subset expectation maximum (2D OSEM) algorithm. Spatial resolution was 2 mm/pixel for PET imaging. After in vivo imaging, the mice were sacrificed and aortas were excised and imaged on a PET scanner using the following parameters: transaxial FOV in 80 mm, axial FOV in 59 mm, spatial resolution less than 1.3 mm, scatter fraction 6.3%. ROI was drawn in the aorta, and the mean of standard uptake values was automatically generated by the software for each ROI.

**Oil Red O Staining of Aorta.** Lipid deposition within the aortas (fixed with 10% formalin) was determined by Oil Red O staining. Briefly, the dissected aorta was opened longitudinally and fixed in 10% formalin for 5–10 min. The fixed aortas were rinsed with 60% propylene glycol for 10 min and then stained with 0.5% Oil Red O solution (in propylene glycol) for 30 min at 37 °C. Finally, the aortas were differentiated with 60% propylene glycol solution for 3 min. Lipids were stained in red. The stained aortas were spread on a black sheet for photographing using a digital camera under identical light conditions with the same photographing parameters. Pictures were analyzed with Image Pro Plus (version 6.0, Media Cybernetics). The quantified results were expressed as the ratio of percentages of the lipid-accumulating lesion area to the total aortic area.

**Histopathological Analysis.** After imaging and radioactivity counting, aortas were fixed in formalin, dehydrated, embedded in paraffin, and sliced in the region of the aortic arch, thoracic aorta, and abdominal aorta that presented obvious plaques. Tissue samples were cut into serial sections 5 μm thick and stained with hematoxylin and eosin for general morphology. For immunohistochemistry analysis, corresponding neighboring sections were stained overnight at 4 °C using primary anti-Mac3 antibody (BD Biosciences) for macrophage detection. Then the primary antibody was detected by incubating the sections with a biotinylated secondary antibody (Santa Cruz Biotech) and with an avidin–biotinylated horseradish peroxidase complex solution according to the manufacturer’s directions. Finally, peroxidase activity was revealed by immersion in diamobenzidine. Digital images of the stained sections were obtained with a scanning light microscope (Leica Microsystems). For von Kossa staining, sections were stained in 1% silver nitrate solution under ultraviolet light for 20 min, then incubated in 5% sodium thioulate, and counterstained with Eosin Y. For immunofluorescence staining, serial sections were incubated overnight with FITC-conjugated HFn or a Cy5.5-conjugated anti-Mac3 antibody (BD Biosciences). The nuclei were counterstained with 4',6-diamidino-2-phenylindole. The stained tissues were examined under a confocal laser scanning microscope (Olympus).

**Macrophage Binding Studies.** We isolated F4/80+/ CD11b+ macrophages from atherosclerotic plaques from ApoE−/− mice that consumed the atherogenic diet for 33 wk. The macrophage binding affinity of 99mTc-HFn was determined by saturation binding experiments using previously described methods with some modifications.24 The freshly isolated macrophages were seeded in a Millipore 96-well filter plate (104 per well), then incubated with increasing concentrations of 99mTc-HFn (4, 8, 12, 24, 32, 96, and 192 nM) at 37 °C for 2 h. The total volume of each well was adjusted to 200 μL of 1% bovine albumin in phosphate-buffered saline (PBS). After incubation, the cells were filtered, washed three times with PBS, and collected, and the radioactivity was determined using a gamma counter (CRC-15 R, Capintec Inc., Ramsey, NJ, USA). Nonspecific binding was determined in the presence of an excess of cold HFn (>100-fold). A saturation binding curve and Scatchard transformation were obtained by nonlinear regression analysis, and the Kd and Bmax (maximum number of binding sites) values of 99mTc-HFn were calculated using GraphPad Prism 6.0 software. All experimental conditions were triplicate.

**Statistical Analyses.** All statistical analyses were performed with SPSS19.0 (IBM, Chicago, IL, USA) and GraphPad Prism 5.01 (GraphPad Software Inc.) software. Results were expressed as mean ± SD. Unpaired Student’s t tests were performed to evaluate the significance of differences between groups. We considered a P value of <0.05 as statistically significant. Correlations between 99mTc-HFn uptake and plaque areas were determined using the Pearson coefficient (r) and P value.

**ASSOCIATED CONTENT**

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsnano.8b04158.

Detailed descriptions for the characterization of 99mTc-HFn, stability experiment, tissue staining, in vivo imaging, blood clearance, and biodistribution studies (PDF).

**AUTHOR INFORMATION**

**Corresponding Authors**

* D. Cheng, E-mail: cheng.dengfeng@zs-hospital.sh.cn. Tel: +86 21 6404-1990.
* H. Shi, E-mail: shi.hongcheng@zs-hospital.sh.cn. Tel: +86 21 6404-1990.
* H. S. Choi, E-mail: hchoi12@mgh.harvard.edu. Tel: +1 617-726-5784.
* X. Yan, E-mail: yanzxy@ibp.ac.cn. Tel: +86 10-6488-8583. Fax: +86 10-6488-8584.

**ORCID**

Minnin Liang: 0000-0002-5152-5240
Kelong Fan: 0000-0001-6285-1913
Hak Soo Choi: 0000-0002-7982-6483
Xiyun Yan: 0000-0002-7290-352X

**Author Contributions**

M. Liang and H. Tan contributed equally to this work.

**Author Contributions**

M.L. and D.C. conceived and designed the experiments. D.C. H.T., and M.L. performed the experiments. M.L., D.C., H.S.C., and X.Y. reviewed, analyzed, and interpreted the data. M.L., D.C., and H.S.C. wrote the paper. All authors discussed the results and commented on the manuscript.

ACS Nano 2018, 12, 9300–9308
ACKNOWLEDGMENTS

The authors declare no competing financial interest.

REFERENCES


